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Abstract
Background and Purpose—Beyond the Framingham Stroke Risk Score (FSRS), prediction of
future stroke may improve with a genetic risk score (GRS) based on Single nucleotide
polymorphisms (SNPs) associated with stroke and its risk factors.
Methods—The study includes four population-based cohorts with 2,047 first incident strokes
from 22,720 initially stroke-free European origin participants aged 55 years and older, who were
followed for up to 20 years. GRS were constructed with 324 SNPs implicated in stroke and 9 risk
factors. The association of the GRS to first incident stroke was tested using Cox regression; the
GRS predictive properties were assessed with Area under the curve (AUC) statistics comparing
the GRS to age sex, and FSRS models, and with reclassification statistics. These analyses were
performed per cohort and in a meta-analysis of pooled data. Replication was sought in a case-
control study of ischemic stroke (IS).
Results—In the meta-analysis, adding the GRS to the FSRS, age and sex model resulted in a
significant improvement in discrimination (All stroke: Δjoint AUC =0.016, p-value=2.3*10-6; IS:
Δ joint AUC =0.021, p-value=3.7*10−7), although the overall AUC remained low. In all studies
there was a highly significantly improved net reclassification index (p-values <10−4).
Conclusions—The SNPs associated with stroke and its risk factors result only in a small
improvement in prediction of future stroke compared to the classical epidemiological risk factors
for stroke.
Keywords
genetic risk prediction; stroke epidemiology; genetic epidemiology; population studies;
cardiovascular risk factors
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Introduction
Stroke is a major and debilitating neurological disease that increases in frequency with age;
it is estimated that in 2030, 23 million persons will have a first-ever stroke resulting in 7.8
million deaths1, 2. Stroke is a complex disease with many modifiable risk factors, and a
substantial genetic component, with heritability estimates varying from 17%3 to 38%4. The
genetic architecture of stroke has been difficult to unravelAlthough recently some findings
have been replicated for specific stroke subtypes,5, 6 initial discoveries of genetic variants
from genome-wide association studies (GWAS) of all stroke (sub-types combined)
outcome7 have failed to replicate. This has led to the concept that different genes may be
involved in different subtypes of stroke.
In contrast, many modifiable clinical and epidemiological risk factors consistently have been
shown to increase the risk for stroke, and also have well replicated risk-associated genetic
variants (single nucleotide polymorphisms – SNPs). Several modifiable risk factors have
been combined into validated clinical prediction tools such as the Framingham Stroke Risk
Score (FSRS), which incorporates systolic blood pressure, diabetes mellitus, cigarette
smoking, prior cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, and the
use of antihypertensive medications8, 9. The FSRS measures traits that may fluctuate in the
short or medium term, thus affecting its predictive properties in any one individual.
Insufficiency of the FSRS has been demonstrated in earlier studies10. Given the increasing
availability of genotyping technology and the promise of using the information in a more
personalized medicine approach, it is timely to investigate whether risk scores incorporating
genetic information will add to the power to predict an individual’s future risk for stroke.
Here we examine the predictive properties of a genetic risk score (GRS) to predict future
stroke in community dwelling stroke-free individuals. We hypothesized that the combined
effect of individual SNPs with small effects would improve prediction. A previous study by
Kathiresan et al. found a GRS based on SNPs from a single class of risk factors, lipids, did
have some value in reclassification, but not in improved discrimination of persons at future
risk for cardiovascular disease11. However, cardiovascular diseases such as stroke have a
complex pathophysiology, which can partially be accounted for in GRS, as they are in
clinical risk scores. Here, we take the approach of including in a risk score, genetic variants
associated with stroke and its multiple risk factors, with the goals of: assessing the potential
of a score, based on SNPs associated with stroke and its risk factors, to predict stroke in
general populations; and investigating whether the score could potentially add to the
predictability of a score based on established stroke clinical and epidemiological risk factors.
As far as we know, we are the first to try to combine not only a disease specific or risk factor
specific set of SNPs into a risk score, but a comprehensive set of risk SNPs from the whole
spectrum of non-behavioral risk factors for stroke. We also investigated the performance of
the GRS in a higher risk population captured in a clinic-based case-control study of ischemic
stroke (IS).
Materials and methods
Our analyses are based on incident cases and stroke-free participants characterized in 4
cohorts participating in the Cohorts for Heart and Ageing Research in Genomic
Epidemiology (CHARGE) consortium. CHARGE is a large consortium of major population-
based prospective cohort studies of cardiovascular health that aims to identify new genetic
variants for multiple quantitative, sub- and clinical factors contributing to health and disease
in older persons12. The individual cohorts and the combined CHARGE genome wide
association study of stroke genes have been previously described7.
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Cohorts and case definition
This analysis is based on the following CHARGE cohorts: the Atherosclerosis Risk in
Communities (ARIC) study13, the Cardiovascular Health Study (CHS)14, the Framingham
Heart Study (FHS)15, 16 and the first cohort of the Rotterdam Study (RS)17. From these
cohorts, we included persons who were stroke-free at the age of 55 or older, of European
descent, and who had complete outcome and genotype data. (Table 1, Supplemental Table
I). For all cohorts, the baseline was established in the late 1980’s and early 1990’s, and all
studies are ongoing. All participants provided informed consent and all studies were
approved by their governing institutional review boards.
All cohorts defined stroke as a focal neurological deficit of presumed vascular cause with a
sudden onset and lasting for at least 24 hours or until death if the participant died less than
24 hours after the onset of symptoms. All suspected events were adjudicated by stroke
experts who reviewed medical records, death certificates, imaging studies, or some
combination of these sources. We report on “All” stroke, which includes ischemic,
hemorrhagic, and unknown sub-type, and separately on ischemic stroke, which is of
presumed cardio-embolic/large vessel/small vessel origin. Subarachnoid hemorrhages were
excluded from all analyses.
Genotyping
Each study separately genotyped or imputed SNPs to the same reference panel (see
Supplemental Table II for methods) and provided data on imputation quality. Due to
imputation, there were no missing genotypes in the datasets. Genotypes for each SNP were
coded in terms of the number of risk alleles.
Identifying risk factors, associated SNPs, and selecting SNPs for inclusion in the risk
score
SNP selection—Based on a literature review, as well as clinical and neurological expert
opinion, we identified 9 domains of established risk factors for stroke that have also been
studied in GWAS: high blood pressure, atherosclerosis, arrhythmia, diabetes, inflammation,
blood constituents, hematologic changes, obesity, elevated lipids, and impaired kidney
function. Within each of these risk factor domains we identified 3–5 traits that contribute to
the overall domain (Table 2), resulting in a total of 33 traits. For each of the 33 traits we
identified from published, in press, and under review genome-wide association studies, SNP
variants that associated with the trait at the standard GWAS significance level (p-value
5*10−8) and for which there was evidence of independent replication (see Supplemental
Table III for a complete list of references). We also included two ischemic stroke-associated
SNPs identified and replicated by the International Stroke Genetics Consortium5. Although
these 4 CHARGE cohorts were often included in the above referenced trait GWAS, in
general the meta-analyses were based on many more subjects, with the proportion of
subjects from these studies ranging between 018 and ~86%19.
In total we identified 334 autosomal SNPs for 34 traits (including stroke). When several
SNPs for a class of risk factors were located in the same loci, we selected the top SNP with
the lowest p–value, from the most recent meta-analyses that included the largest number and
thus had the largest power and highest precision. In some cases the same SNP was
associated with multiple traits. For this, we assigned the SNP to the clinical rather than the
sub-clinical trait (for example, diabetes over fasting glucose levels). After these exclusions
we included 324 SNPs (see Supplemental Table III), including 28 traits with multiple SNPs
and 6 with single SNPs.
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Statistics: Construction of the risk score—The construction of the risk score (Figure
1) is described in detail in the Supplemental Methods. In short, weighted risk scores were
created for each of the 28 traits with multiple SNPs. Weights were the effects, or log odds
ratios, of the risk allele on the outcome it was originally associated to. This effect was
multiplied by the number of risk alleles (allele dosage: 0,1 or 2) the individual carried; for
imputed SNPs, where the dosage is estimated, this value can obtain any fraction between 0
and 2. The risk score was the sum of the weight*dosage product for all SNPs within the trait.
For the traits that had only one SNP associated (singletons), the allele dosage was used. Risk
scores and singletons entered as covariates in Cox regressions with age as the time-to-event
variable. Each cohort calculated a modified FSRS, which differed from the original FSRS
only in the omission of the age variable.
Analysis
The individual risk predictions were calculated from five regression models: model 1
included sex only, model 2 included the GRS only, model 3 included sex and the GRS,
model 4 included sex and the mFSRS, and model 5 included sex, the GRS and the mFSRS.
CHS models also included a variable for study site and the FHS made adjustments for
family relationships15, 16.
Calculation and comparison of the ROC curves
Receiver-operated characteristic (ROC) curves with corresponding areas under the curve
(AUC) [95% confidence interval for each model] were created from the predicted risks
derived from the regression models. The model AUCs were tested against the null model
(AUC=0.50) and compared to each other. The latter comparisons were tested with the
Hanley-McNeil test for comparison of correlated AUCs20. The Hanley-McNeil test requires
a correlation between the AUCs, which was obtained using the metacor package for R21.
Finally, we estimated meta-AUCs [95% confidence intervals] based on all cohorts combined
using an inverse variance weighted meta-analysis.
Reclassification statistics
In secondary analyses we assessed the added clinical value of the genetic risk score over the
FSRS using two statistics: the net reclassification improvement (NRI) without cut-off values
(continuous NRI), which gives a summary of the number of subjects with reclassified
predicted case status based on the new score; and the integrated discrimination improvement
(IDI)22, 23, which describes the ability of the score to discriminate between cases and non-
cases.
External replication
We investigated the predictive power of the same GRS in a German case-control set of IS
previously described.5, 6 Cases (N=985) were the German samples of the Wellcome Trust
Case Control Consortium 2 (WTCCC2), recruited in the Klinikum Grosshadern, Department
of Neurology, Ludwig-Maximilians-University in Munich, Germany. Controls (N=596)
were participants in the KORAgen study, residing in the Augsburg area in Germany (http://
www.gsf.de/kora/en/english.html), with no history of stroke or transient ischemic attack.
The studies were approved by the respective local Institutional Review Boards and all
subjects gave informed consent. Details on genotyping and imputation are given in
Supplemental Table II. To account for the case-control design we used a logistic regression
model, adjusted for age and sex to estimate the trait scores and their association with stroke.
As details on the elements of the FSRS were not generally available for the subjects in this
cohort, we were unable to perform replication efforts for the FSRS comparisons in this
cohort.
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Results
During follow-up, 2047 participants from the 22,720 developed first ever strokes, including
1523 ischemic strokes. The RS (N of cases=783, 13.5%) and CHS (N of cases=560, 17.1%)
participants were older and had more incident stroke events (Table 1) than the FHS (N of
cases=206, 4.8%) and ARIC (N of cases=498, 5.3%). participants. These cohorts also had a
higher prevalence of hypertension than the other two. Most smokers were found in ARIC
and RS (Supplemental Table I). The number of risk alleles had similar distribution in all
cohorts (Supplemental Figure I) reflecting the population-based study designs of all cohorts.
Predicted risks from the models including the GRS and/or mFSRS were significantly higher
in cases than in individuals who remained stroke-free (p-value <0.001, Supplemental Table
IV). Across cohorts, the AUC including only the GRS (Table 3, Supplemental Figure II)
ranged from 0.563 to 0.617 for all stroke. When combining the findings of the cohorts, the
meta-AUC was 0.578 (p-value=9*10−10 compared to the model with only sex). For the
model with sex and the GRS, the all stroke meta-AUC was 0.572, which was statistically
different from the model including only sex (p-value=9*10−18). For IS, the AUC of the
model including only the GRS, ranged from 0.585 to 0.627 across cohorts; the meta-AUC
was 0.592. For the combined model with sex and the GRS, meta-AUC was 0.597 (p-value
compared to sex only = 2*10−19). (Table 4, Supplemental Figure II)
Comparison between the genetic and clinical risk scores
In all cohorts, the AUC for the mFSRS was higher than those seen for the GRS. For all
stroke, the mFSRS AUC ranged from 0.587 in the RS to 0.709 in the FHS, with a highly
significant meta-AUC of 0.621 (Table 3, Supplemental Figure III). In all cohorts, there was
a low correlation between the absolute predicted risks derived from mFSRS and those
derived from the genetic risk score (meta-correlation 0.012, meta p-value 0.13). The full
model (sex, mFSRS and the GRS) improved prediction significantly in all cohorts except the
FHS, the cohort that was used to develop the original FSRS. The meta-AUC for the full
model was 0.637. When the full model is compared to the model with sex and mFSRS, the
GRS gives an improvement of 0.016 (p-value=2*10−6) over classical risk factors. For IS, the
meta-AUC for the full model was 0.654, with an improvement of 0.021 (p-value=4*10−7)
between the full model and the sex and mFSRS model (Table 4, Figure 2). Compared to the
model based on sex and the FSRS, the GRS yielded a significant NRI (improvement ranging
from 0.18 to 0.32 for all stroke and from 0.24 to 0.28 for IS, p-values ≤ 1.1*10−4) and IDI
(improvement ranging from 0.005 to 0.02 for all stroke and from 0.008 to 0.021 for ischemic
stroke, p-values ≤ 5*10−5) (Supplemental Table V).
Replication
We replicated our findings in the case-control sample of the WTCCC2. The AUC of the sex,
age and GRS model was higher than the model with age and sex alone (difference between
the two models = 0.014 (p-value 0.04); Supplemental Table VI, Supplemental Figure IV).
The reclassification statistics (continuous NRI = 0.309, p-value < 1*10−5, and IDI = 0.018,
p-value < 1*10−5) showed a small but highly significant improvement in prediction of
ischemic stroke when the GRS was added to models based on age and sex.
Discussion
We assessed the predictive properties of a genetic risk score based on stroke risk factors in a
population-based sample of 2,047 well-characterized incident stroke cases among 22,720
initially stroke-free individuals. We found that a genetic risk score that included genome-
wide associated SNPs for 9 domains of risk factors plus stroke provided a small but very
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significant and consistent improvement in the prediction of an individual’s risk for future
stroke. This small difference was observed when the GRS was compared to sex adjusted
models as well as to a widely used clinical-epidemiological risk score. Similar results were
found when the score was applied in a large clinic-based case control sample.
Age is an important predictor of many diseases, in particular a late onset outcome as stroke.
A large part of the discrimination of a prediction model is therefore determined by age,
biasing the interpretation of the value of the other variables, in our case genetic predictors.
In this study, we controlled for age as the follow-up time so we could clearly assess whether
genetic information could improve prediction conditional on the person’s age It is important
to note that the AUCs are therefore in general lower than reported in the literature. For
instance, in the Rotterdam Study, we find much lower AUCs in the Cox approach with age
as the timescale (AUC for FSRS=0,59; p-value=1*10−14) than in the logistic model where
age is a covariate, essentially examining the GRC with all subjects of the mean age (AUC
for FSRS =0.65; p-value=2*10−39).
The GRS performs significantly worse than the age+sex model in the replication, but this
was not the primary comparison we wished to test. Our goal was to test whether the GRS
has added value over and above the clinical risk factors, and we do indeed find modest (Δ
AUC (discovery) = 0.021, Δ AUC (replication) = 0.024) but significant (p-value (discovery)
= 3.66*10−7, p-value (replication) = 0.03) (Table 4 & Supplemental Table 6) improvement
in the AUCs in both the discovery and replication analyses. The difference in p-values most
likely reflects the differences in sample size of the discovery and replication cohorts.
Before interpreting the findings it is important to note the assumptions underlying the
construction of the score and consider the limitations: 1) The relationships between variants
and risk factors, and between risk factor and outcome are always the same, ie (log)linear ; 2)
Each variant associated with the stroke risk factor, will also be a risk variant for stroke; 3)
The effect is proportional to the number of risk variants (0, 1, or 2 copies) (Whereas in
reality, the variant may have dominant or recessive effect on stroke); 4) There is no
interaction between genetic variants (we did not find evidence for interaction between the
loci in this study). Each of these assumptions is necessary when creating such a score, but
they may be simplifications of the true underlying biological model.
Previous studies have examined the association of clinical disease to SNPs that associate
with risk factors for the disease. For example studies by Ehret et al and Wain et al24, 25
showed genetic variants associated with blood pressure traits were also associated with
stroke. Paynter et al.26 assessed the performance of a GRS based on a small number of SNPs
associated to cardiovascular disease (CVD) to predict CVD outcomes including stroke. They
did not find their genetic risk score improved prediction over the traditional risk factors. A
similar conclusion has been reached by other investigators examining risk SNPs for a single
class of risk factors11, 27, 28, although recently some authors have found risk differences
between GRS quintiles for stroke29, 30. Here, we present a different approach: we test a
single outcome (stroke) to a risk score based on SNPs associated with a variety of risk
factors. This approach takes into account the complexity of disease and our results suggest
incorporating such genetic information into risk scores may be a fruitful even in a very
complex disease such as stroke.
Our analyses showed that the genetic risk score improved the discrimination over the
mFSRS, although the absolute increase in prediction was small. The correlation between the
mFSRS and genetic risk score was low suggesting the genetic variants, which are constant
over the lifetime, can add to the information provided by a single assessment of variable risk
factors such as blood pressure and glucose levels. Supporting evidence of this improvement
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is reflected in the improved reclassification statistics. Although reclassification is seen as
clinically relevant, this finding should be interpreted with caution as the value of the IDI has
been questioned31, and both the IDI and NRI may be inflated32.
One of the most notable findings is that the GRS worked similarly in 3 of the 4 different
cohorts, which, although all population-based, had different age distributions. The absence
of an improvement in prediction in the FHS beyond the mFSRS may well reflect overfitting
of the mFSRS in this cohort, as the original FSRS was developed on the FHS source
population. Another important finding is that AUCs and AUC improvements are higher and
p-values are lower for ischemic stroke compared to all stroke, despite a smaller number of
cases. This difference may reflect the fact IS is an etiologically more homogenous
phenotype, and the risk factors we selected are better associated to ischemic stroke than to
all stroke. This is consistent with GWAS discoveries which thus far have been limited to
defined subtypes5, 6. It will be valuable to have both better clinical prediction models and
improved genetic prediction models targeting ischemic and hemorrhagic stroke as two
distinct clinical entities, resulting in an improvement to the FSRS, which has a low AUC.
The combined clinical-genetic-and epidemiological risk model may become a valuable tool
for clinicians, and such differential risk models for ischemic versus hemorrhagic stroke may
even help guide treatment decisions.
As array-based genotyping becomes more and more affordable and widely available, the
possibility of multi-marker genetic risk profiling as part of daily medical practice becomes
more realistic. As we show in this article, clinical risk profiling alone is still superior in
predictive power to genetic risk profiling alone in the setting of a population-based cohort
study of middle-aged and elderly subjects. In current clinical practice, some risk factors like
diabetes, hypertension, dyslipidemia and atrial fibrillation often come to light only after a
stroke has occurred. Paroxysmal atrial fibrillation may be missed during regular ECG
registration or even during a 24-hour Holter monitoring. To act pre-emptively on these risk
factors, a subject would have to be screened on a regular basis and at least every few years
depending on their age and perhaps other factors, we suggest that their genetic profile might
help select persons at higher stroke risk for more frequent or thorough screening. A genetic
risk score could be estimated at a single time point early in life, and persons with a higher
genetic risk be targeted for more rigorous lifestyle counseling before risk factors emerge,
more stringent clinical follow-up for control of risk factors, and even preventive medication
such as platelet aggregation inhibitors, statins or antihypertensive medications in persons
with borderline levels of these risk factors.. We anticipate that with rapid developments in
unraveling the genetic origin of various stroke risk factors, the genetic prediction of stroke
risk will improve in the near future improving the efficacy of early genetic risk profiling and
targeted preventive interventions. This study in a large prospectively followed population
based epidemiological cohort yields a proof of principle that genetic variants associated with
risk factors for stroke combined into a risk score improves discrimination of at-risk patients.
These results are based on stroke-free individuals living in the community who may be
examined in first line health services, and are replicated in individuals who have had a
stroke and are identified in the hospital setting. However the small improvement we found is
unlikely to be of clinical significance;. and only brings a small improvement over scores
based on clinical information. In the future, however, as our understanding of the genetic
architecture of stroke -its sub-types and risk factors - improves, GRS could become
powerful additions to clinically measured risk factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow diagram: Construction of the Genetic Risk Score for Stroke
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Figure 2. ROC curves for the discovery cohorts, ischemic stroke: CHARGE Genetic Risk Score
for Stroke
Each lettered panel gives the sensitivity*(1-specificity) curves for the clinical prediction (sex
+FSRS), prediction based on the GRS, and on the two combined. Panels: A=ARIC, B=CHS,
C=FHS, D=RS.
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Table 2
Traits included in the CHARGE Genetic Risk Score for Stroke model
Risk score group SNPs implicated in:
Arrythmia Atrial fibrillation, PR-interval, RR-interval
Atherosclerosis Intima-media thickness, subclinical coronary artery disease, clinical coronary artery disease
Blood pressure Hypertension, pulse pressure, mean arterial pressure
Diabetes Type 2 diabetes, fasting glucose levels, insulin levels
Hematology White blood cell count, hemoglobin, hematocrit, platelet count, mean platelet volume
Inflammation Fibrinogen levels, C-reactive protein
Lipids Total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides
Nephrology Estimated glomerular filtration rate, albumin/creatinine ratio, creatinine, end-stage renal disease
Obesity Body mass index, waist-to-hip ratio, waist circumference
Stroke Stroke genome-wide association studies
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